The placebo arm in clinical studies for treatment of Psychiatric Disorders: A Regulatory Dilemma

European Neuropsychopharmacology

Volumn 22, Issue 11, 2012, Pages 804-811

  Gispen de Wied, Christine ^a   Stoyanova, Violeta ^a   Yu, Yang ^a   Isaac, Maria ^b   Pani, Luca ^c   de Andres Trelles, Fernando ^d  

^a MEDICINES EVALUATION BOARD   (Netherlands)

^b EUROPEAN MEDICINES AGENCY   (United Kingdom)

^c ITALIAN MEDICINES AGENCY   (Italy)

^d Advanced Therapies and Biotechnology   (Spain)

Author keywords

Clinical trial; Placebo; Psychiatry; Psychopharmacology; Regulatory science

Indexed keywords

AGOMELATINE; AMFEBUTAMONE; ARIPIPRAZOLE; CITALOPRAM; DULOXETINE; ESCITALOPRAM; HALOPERIDOL; OLANZAPINE; PALIPERIDONE; PAROXETINE; PLACEBO; QUETIAPINE; RISPERIDONE;

ARTICLE; ASSAY; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; FEASIBILITY STUDY; MAJOR DEPRESSION; PRIORITY JOURNAL; SCHIZOPHRENIA; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; CONTROLLED CLINICAL TRIALS AS TOPIC; DEPRESSIVE DISORDER, MAJOR; DRUG RESISTANCE; DRUGS, INVESTIGATIONAL; EUROPEAN UNION; HUMANS; PLACEBO EFFECT; PSYCHOPHARMACOLOGY; REPRODUCIBILITY OF RESULTS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 84867523620     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2012.03.007     Document Type: Article

References (19)

1. Boon W.P., Moors E.H., Meijer A., Schellekens H. Conditional approval and approval under special circumstance as regulatory instruments for stimulating responsible drug innovation in Europe. Clin. Pharmacol. Ther. 2010, 88(6):848-853.
2. Chen Y.F., Wang S.J., Khin N.A., Hung H.M., Laughren T.P. Trial design issues and treatment effect modeling in multi-regional schizophrenia trials. Pharm. Stat. 2010, 9(3):217-229.
3. Eichler H.G., Pignatti F., Flamion B., Leufkens H., Breckenridge A. Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma. Nat. Rev. Drug Discov. 2008, 7(10):818-826.
4. Eichler H.G., Abadie E., Breckenridge A., Flamion B., Gustafsson L.L., Leufkens H., Rowland M., Schneider C.K., Bloechl-Daum B. Bridging the efficacy-effectiveness gap: a regulatory's perspective on addressing variability of drug response. Nat. Rev. Drug Discov. 2011, 10(7):495-506.
5. Fournier J.C., DeRubeis R.J., Hollon S.D., Dimidjian S., Amsterdam J.D., Shelton R.C., Fawcett J. Antidepressant drug effects and depression severity: a patient-level meta-analysis. J. Am. Med. Assoc. 2010, 303(1):47-53.
6. Fountoulakis K.N., Möller H.J. Efficacy of antidepressants: a re-analysis and re-interpretation of the Kirsch data. Int. J. Neuropsychopharmacol. 2011, 14(3):405-412.
7. Harmer C.J., Cowen P.J., Goodwin G.M. Efficacy markers in depression. J. Psychopharmacol. 2011, 25(9):1148-1158.
8. Horder J., Matthews P., Waldmann R. Placebo, Prozac and PLoS: significant lessons for psychopharmacology. J. Psychopharmacol. 2010, 22.
9. Isaac M., Koch A. The risk of death among adult participants in trials of antipsychotic drugs in schizophrenia. Eur. Neuropsychopharmacol. 2010, 20(3):139-145.
10. Khin N.A., Chen Y.F., Yanf Y., Yang P., Laughren T.P. Exploratory analysis of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications. J. Clin. Psychiatry 2011, 72(4):467-468.
11. Kirsch I., Deacon B.J., Huedo-Medina T.B., Scoboria A., Moore T.J., Johnson B.T. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med. 2008, 5(2):e45.
12. Melander H., Salmonson T., Abadie E., van Zwieten-Boot B. A regulatory apologia-a review of placebo-controlled studies in regulatory submissions of new-generation antidepressants. Eur. Neuropsychopharmacol. 2008, 18(9):623-627.
13. Mora M.S., Nestoriuc Y., Rief W. Lessons learned from placebo groups in antidepressant trials. Philos. Trans. R. Soc. B 2011, 366:1879-1888.
14. Raine J., Wisse L., Blackburn S., Eichler H.G., Breckenridge A. European perspective on risk management and drug safety. Clin. Pharmacol. Ther. 2011, 89(5):650-654.
15. Regnstrom J., Koenig F., Aronsson B., Reimer T., Svendsen K., Tsigkos S., Flamion B., Eichler H.G., Vamvakas S. Factors associates with success of marketing authorisation applications for pharmaceutical drugs submitted to the European Medicines Agency. Eur. J. Clin. Pharmacol. 2010, 66(1):39-48.
16. Sinyor M., Levitt A.J., Cheung A.H., Schaffer A., Kiss A., Dowlati Y., LanctÔt K.L. Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? Results from pooled and meta-analyses. J. Clin. Psychiatry 2010, 71(3):270-279.
17. Storosum J.G., Elferink A.J.A., Zwieten van B.J., Brink van den W., Gersons B.P.R., Broekmans A.W. Short-term efficacy of tricyclic antidepressants revisited: a meta-analytic study. Eur. Neuropsychopharmacol. 2001, 11:173-179.
18. Storosum J.G., Elferink A.J., van Zwieten B.J., van den Brink W., Huyser J. Natural course and placebo response in short-term, placebo-controlled studies in major depression: a meta-analysis of published and non-published studies. Pharmacopsychiatry 2004, 37(1):32-36.
19. Storosum J.G., Elferink A.J., van Zwieten B.J. Schizophrenia: do we really need placebo-controlled studies?. Eur. Neuropsychopharmacol. 1998, 8(4):279-286.